
=> d his

(FILE 'HOME' ENTERED AT 14:04:27 ON 10 FEB 2006)

	FILE	'REGIS	STRY	ENTE	ERED	ΑT	14:	04:33	ON	10	FEB	2006
L1			STRU	CTURE	E UPI	LOAI	DED					
L2		50	S L1									
L3			STRU	CTURE	E UPI	LOAI	DED					
L4		13	S L3									
L5			STRU	CTURE	E UPI	LOAI	DED					
L6		8	S L5									
L7		138	S L5	SSS	FUL							

FILE 'CAPLUS' ENTERED AT 14:09:07 ON 10 FEB 2006 L8 7 S L7

=> d ibib abs hitstr total



```
chain nodes :
   21 22 26 27 29 30
ring nodes :
   1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
chain bonds :
   8-26 8-27 9-29 9-30 13-21
                             15-22 16-31
ring bonds :
   1-2 1-6 2-3 3-4 4-5
                        5-6 5-7 6-11 7-8 8-9 9-10 10-11 12-13 12-16 13-14
   14-15 15-16
exact/norm bonds :
   1-2 1-6 2-3 3-4 4-5 5-6 5-7
                                 6-11 7-8 8-9 8-26 8-27 9-10 9-29 9-30 10-11
   12-13 12-16 13-14 13-21 14-15
                                 15-16 15-22 16-31
G1:C,O,S,N
G2:0,S
```

```
G4:O,S,N
G5:H,CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu
```

G3:C,N

Match level:
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 21:CLASS 22:CLASS 26:CLASS 27:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS

ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

AdCESSION NUMBER: 2005:973681 CAPLUS

DOCUMENT NUMBER: 143:318709

TITLE: Blockade of PI3Ky suppresses joint inflammation and damage in mouse models of rheumatoid arthritis

AUTHOR(S): Camps, Montserrat; Rueckle, Thomas; Ji, Hong;

Ardissone, Vittoria; Rintelen, Felix; Shaw, Jeffrey; Ferrandi, Chiara; Chabert, Christian; Gillieron, Corine; Francon, Bernard; Martin, Thierry; Gretener, Denise; Perrin, Dominique; Leroy, Didier; Vitte, Pierre-Alain; Hirsch, Emilio; Wymann, Matthias P.;

Cirillo, Rocco; Schwarz, Matthias K.; Rommel,

Christian

CORPORATE SOURCE: Serono Pharmaceutical Research Institute, Serono

International S.A., Geneva, 1228, Switz.

SOURCE: Nature Medicine (New York, NY, United States) (2005)

11(9), 936-943

CODEN: NAMEFI; ISSN: 1078-8956

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal LANGUAGE: English

AB Phosphoinositide 3-kinases (PI3K) have long been considered promising drug targets for the treatment of inflammatory and autoimmune disorders as well as cancer and cardiovascular diseases. But the lack of specificity, isoform selectivity and poor biopharmaceutical profile of PI3K inhibitors have so far hampered rigorous disease-relevant target validation. Here we describe the identification and development of specific, selective and orally active small-mol. inhibitors of PI3K γ (encoded by Pik3cg). We show that Pik3cg-/- mice are largely protected in mouse models of rheumatoid arthritis; this protection correlates with defective neutrophil migration, further validating PI3K γ as a therapeutic target. We also describe that oral treatment with a PI3Ky inhibitor suppresses the progression of joint inflammation and damage in two distinct mouse models of rheumatoid arthritis, reproducing the protective effects shown by Pik3cg-/- mice. Our results identify selective PI3Kγ inhibitors as potential therapeutic mols. for the treatment of chronic inflammatory disorders such as rheumatoid arthritis.

IT 648450-29-7P, AS 605240 865188-81-4P, AS 605091

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(blockade of PI3Ky suppresses joint inflammation and damage in mouse models of rheumatoid arthritis)

RN 648450-29-7 CAPLUS

CN 2,4-Thiazolidinedione, 5-(6-quinoxalinylmethylene)- (9CI) (CA INDEX NAME)

RN 865188-81-4 CAPLUS

CN 2,4-Thiazolidinedione, 5-[(3,4-dihydro-4-methyl-2H-1,4-benzoxazin-7-yl)methylene]- (9CI) (CA INDEX NAME)

REFERENCE COUNT:

THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:120737 CAPLUS

DOCUMENT NUMBER: 142:219270

TITLE: Preparation of 2-imino-4-(thio)oxo-5-

polycyclovinylazolines as PI3 kinase inhibitors

INVENTOR(S): Rueckle, Thomas; Shaw, Jeffrey; Church, Denis; Covini,

David

PATENT ASSIGNEE(S): Applied Research Systems Ars Holding N.V., Neth.

SOURCE: PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATE	PATENT NO.						DATE		APPLICATION NO.						DATE			
WO 2	WO 2005011686					A1		20050210		WO 2004-EP51625					20040727			
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	ΒZ,	CA,	CH,	
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,	
		GE,	GH,	GM,	HR,	HU,	ID,	ΙĻ,	IN,	IS,	JP,	ΚE,	KG,	KP,	KR,	KZ,	LC,	
		LK,	LR,	LS,	LT,	LU,	LV,	ΜA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NI,	
		NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,	
		ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW	
	RW:	BW,	GH,	GM,	KΕ,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	
		ΑZ,	BY,	KG,	KZ,	MD,	RU,	ТJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	
		EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	ΙT,	LU,	MC,	ΝL,	PL,	PT,	RO,	SE,	
		SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	NΕ,	
		SN,	TD,	TG														
PRIORITY	IORITY APPLN. INFO.:								EP 2003-102313						A 20030728			

OTHER SOURCE(S): MARPAT 142:219270

Ι

GI

AB The title compds. I [A = 5-8 membered heterocyclic or carbocyclic group which may be fused with an aryl, heteroaryl, cycloalkyl or

heterocycloalkyl; X = S, O, NR3, Y = S, O; R1 = H, CN, CO2H, acyl, etc.; R2 = H, halo, acyl, NH2, etc.; G = alkoxy, alkyl, CN, etc.; R3 = H, alkyl; with provisos], useful in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries, were prepared and formulated. Thus, reacting 5-benzo[1,3]dioxol-5-ylmethylene-2-iminothiazolidin-4-one (preparation given) with 2-chlorobenzenesulfonyl chloride afforded 17% II. The tested compds. I showed IC50 of < 10 μ M with regard to PI3Ky.

IT 648450-30-0P 843641-34-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2-imino-4-(thio)oxo-5-polycyclovinylazolines as PI3 kinase inhibitors)

RN 648450-30-0 CAPLUS

CN 4-Thiazolidinone, 5-(6-quinoxalinylmethylene)-2-thioxo- (9CI) (CA INDEX NAME)

RN 843641-34-9 CAPLUS

CN 4(5H)-Thiazolone, 2-(methylthio)-5-(6-quinoxalinylmethylene)- (9CI) (CA INDEX NAME)

2

REFERENCE COUNT:

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:927010 CAPLUS

DOCUMENT NUMBER: 141:376382

TITLE: Pin1-modulating compounds and methods of use for the

treatment of Pin1-associated diseases, including

US 2003-463271P

P 20030416

cancer

INVENTOR(S): Bao, Lere; Kimzey, Amy

PATENT ASSIGNEE(S): Pintex Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 189 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.					KIND DATE				APPL	ICAT:	DATE						
WO 2004093803				A2 20041104			1	WO 2	 004-1		20040416						
	W:	ΑE,	AG,	AL,	AM,	ΑT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	ΚP,	KR,	ΚZ,	LC,
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NI,
		NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,
		ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	ŲΖ,	VC,	VN,	YU,	ZA,	ZM,	ZW
	RW:	BW,	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	ΑZ,
		BY,	KG,	KZ,	MD,	RU,	ТJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,
		ES,	FI,	FR,	GB,	GR,	ΗU,	ΙE,	IT,	LU,	MC,	ΝL,	PL,	PT,	RO,	SE,	SI,
		SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	ΝE,	SN,
		TD,	TG														

PRIORITY APPLN. INFO.: OTHER SOURCE(S): MARPAT 141:376382

AB The invention is directed to modulators, e.g., inhibitors, of Pin1 and Pin1-related proteins and the use of such modulators for treatment of Pin1 associated states, e.g., for the treatment of cancer. The present invention aims to provide photochemotherapeutic compds. with increased specificity as compared with known agents.

IT 676646-30-3 677004-75-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Pin1-modulating compds. for treatment of Pin1-associated diseases, including cancer)

RN 676646-30-3 CAPLUS

CN 3-Thiazolidinebutanoic acid, 4-oxo-5-(6-quinoxalinylmethylene)-2-thioxo-(9CI) (CA INDEX NAME)

RN 677004-75-0 CAPLUS

CN 3-Thiazolidinebutanoic acid, 5-[(3,4-dihydro-4-methyl-2H-1,4-benzoxazin-7-yl)methylene]-4-oxo-2-thioxo-(9CI) (CA INDEX NAME)

L8 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS ON STN ACCESSION NUMBER: 2004:546505 CAPLUS

DOCUMENT NUMBER: 141:106478

TITLE: Preparation of benzoxazines and related compounds as

inhibitors of PI3Ks

INVENTOR(S): Gogliotti, Rocco Dean; Muccioli, Keri Lynn; Para,

Kimberly Suzanne; Visnick, Melean Warner-Lambert Company Llc, USA

SOURCE: PCT Int. Appl., 77 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT ASSIGNEE(S):

```
PATENT NO.
                        KIND
                               DATE
                                          APPLICATION NO.
                                                                 DATE
                                           -----
                        - - <del>- -</del>
                               -----
     WO 2004056820
                         A1
                               20040708
                                           WO 2003-IB5887
                                                                  20031210
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
            GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
            LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
            OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
            TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
            BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
            ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
            TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    CA 2510851
                               20040708
                                         CA 2003-2510851
                         AΑ
                                                                  20031210
    EP 1581529
                         A1
                               20051005
                                           EP 2003-813672
                                                                  20031210
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
    BR 2003017572
                         Α
                               20051122
                                           BR 2003-17572
                                                                  20031210
    US 2004138199
                                           US 2003-743852
                         Α1
                               20040715
                                                                  20031222
PRIORITY APPLN. INFO.:
                                           US 2002-435227P
                                                               P 20021220
                                                               W 20031210
                                           WO 2003-IB5887
OTHER SOURCE(S):
                      MARPAT 141:106478
```

GI

Ι

AB Title compds. I [W = O, S, (un) substituted NH; Q = bond, CH2, CHMe, CMe2; D, E = CH2, CHMe, CMe2; A = bond, SO2, CO, CO2, CONH, CSNH; L = bond, alkylene, CH:CH, oxaalkylene, thialakylene, oxoalkylene, oxoalkylenoxy, carbamoylalkylene, aminoalkylene; Y = CO, CS; K = NH, O, S, CH2; R1 = R1 = H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, heteroaryl; R2, R4 = H, F, CF3, Me; R3 = H, CH2CO2H, Ph, alkyl, alkenyl; R5 = H, alkoxy, alkyl, NO2, (un) substituted NH2, alkylthio, F, Cl] were prepared for use as inhibitors of PI3Ks in the treatment of inflammatory diseases, cardiovascular diseases, and cancers. Thus, 4,2-Br(O2N)C6H3OH was reduced to the amine, N-protected, and cyclized with BrCH2CH2Br to 4-tert-butoxycarbonyl-6-bromo-2,3-dihydrobenz[1,4]oxazine which was converted to the 6-formyl derivative, deblocked, and treated with rhodanine to give the benzoxazine II. IIhad IC50 for inhibition of PI3Ky of 0.056 μM.

ΙT 719309-03-2P 719309-04-3P 719309-05-4P 719309-06-5P 719309-07-6P 719309-08-7P 719309-09-8P 719309-10-1P 719309-11-2P 719309-12-3P 719309-13-4P 719309-14-5P 719309-15-6P 719309-16-7P 719309-17-8P 719309-18-9P 719309-19-0P 719309-20-3P 719309-21-4P 719309-22-5P 719309-23-6P 719309-24-7P 719309-25-8P 719309-26-9P 719309-27-0P 719309-28-1P 719309-29-2P 719309-30-5P 719309-31-6P 719309-32-7P 719309-33-8P 719309-34-9P 719309-35-0P 719309-36-1P 719309-37-2P 719309-38-3P 719309-39-4P 719309-40-7P 719309-41-8P 719309-42-9P 719309-43-0P 719309-44-1P 719309-45-2P 719309-46-3P 719309-47-4P 719309-48-5P 719309-49-6P 719309-50-9P 719309-51-0P 719309-52-1P 719309-53-2P 719309-54-3P 719309-55-4P 719309-56-5P 719309-57-6P 719309-58-7P 719309-59-8P 719309-60-1P 719309-61-2P 719309-62-3P 719309-63-4P 719309-64-5P 719309-65-6P 719309-66-7P 719309-67-8P 719309-68-9P

RN

CN

```
719309-69-0P 719309-70-3P 719309-71-4P
719309-72-5P 719309-73-6P 719309-74-7P
719309-75-8P 719309-76-9P 719309-77-0P
719309-78-1P 719309-79-2P 719309-80-5P
719309-81-6P 719309-82-7P 719309-83-8P
719309-84-9P 719309-85-0P 719309-86-1P
719309-87-2P 719309-88-3P 719309-89-4P
719309-90-7P 719309-91-8P 719309-92-9P
719309-93-0P 719309-94-1P 719309-95-2P
719309-96-3P 719309-97-4P 719309-98-5P
719309-99-6P 719310-00-6P 719310-01-7P
719310-02-8P 719310-03-9P 719310-04-0P
719310-05-1P 719310-06-2P 719310-07-3P
719310-08-4P 719310-09-5P 719310-10-8P
719310-11-9P 719310-12-0P 719310-13-1P
719310-14-2P 719310-15-3P 719310-16-4P
719310-17-5P 719310-18-6P 719310-19-7P
719310-20-0P 719310-21-1P 719310-22-2P
719310-23-3P 719310-24-4P 719310-25-5P
719310-26-6P 719310-27-7P 719310-28-8P
719310-29-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
   (preparation of benzoxazines and related compds. as inhibitors of PI3Ks)
719309-03-2 CAPLUS
2H-1,4-Benzoxazine, 4-benzoyl-3,4-dihydro-6-[(4-oxo-2-thioxo-5-
thiazolidinylidene)methyl] - (9CI) (CA INDEX NAME)
```

RN 719309-04-3 CAPLUS

CN 2H-1,4-Benzoxazine, 4-(cyclohexylcarbonyl)-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-05-4 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

RN 719309-06-5 CAPLUS

CN 4-Thiazolidinone, 5-[[4-[(3,5-dimethylphenyl)methyl]-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo-(9CI) (CA INDEX NAME)

RN 719309-07-6 CAPLUS

CN 4-Thiazolidinone, 5-[[4-[[3,5-bis(1,1-dimethylethyl)phenyl]methyl]-3,4-dihydro-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo-(9CI) (CA INDEX NAME)

RN 719309-08-7 CAPLUS

CN 4-Thiazolidinone, 5-[[5-[(3,5-dimethoxyphenyl)methyl]-2,3,4,5-tetrahydro-1,5-benzoxazepin-7-yl]methylene]-2-thioxo- (9CI) (CA INDEX NAME)

RN 719309-09-8 CAPLUS

CN 4-Thiazolidinone, 5-[[5-[(3,5-dimethylphenyl)methyl]-2,3,4,5-tetrahydro-1,5-benzoxazepin-7-yl]methylene]-2-thioxo-(9CI) (CA INDEX NAME)

RN 719309-10-1 CAPLUS

CN 2H-1,4-Benzoxazine, 4-benzoyl-3,4-dihydro-3-methyl-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-11-2 CAPLUS

CN 4-Thiazolidinone, 5-[[4-[(3,5-dimethylphenyl)methyl]-3,4-dihydro-3-methyl-2H-1,4-benzoxazin-6-yl]methylene]-2-thioxo-(9CI) (CA INDEX NAME)

RN 719309-12-3 CAPLUS

CN 4-Thiazolidinone, 5-[(3,4-dihydro-2H-1,4-benzoxazin-6-yl)methylene]-2-thioxo-(9CI) (CA INDEX NAME)

RN 719309-13-4 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-4-(2-naphthalenylacetyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-14-5 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(4-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

RN 719309-15-6 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(3-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

RN 719309-16-7 CAPLUS

CN 2H-1,4-Benzoxazine, 4-(3,5-dimethoxybenzoyl)-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-17-8 CAPLUS

CN 2H-1,4-Benzoxazine, 4-[(3,4-dichlorophenyl)acetyl]-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c} C1 \\ C1 \\ CH_2 \\ C = 0 \end{array}$$

RN 719309-18-9 CAPLUS

CN 4-Thiazolidinone, 5-[[2,3,4,5-tetrahydro-5-(2-phenylethyl)-1,5-benzoxazepin-7-yl]methylene]-2-thioxo-(9CI) (CA INDEX NAME)

RN 719309-19-0 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxylic acid, 2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-, phenyl ester (9CI) (CA INDEX NAME)

RN 719309-20-3 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxylic acid, 2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-, 4-methylphenyl ester (9CI) (CA INDEX NAME)

RN 719309-21-4 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(phenylacetyl)- (9CI) (CA INDEX NAME)

RN 719309-22-5 CAPLUS

CN 2H-1,4-Benzoxazine, 4-[(3,4-dimethoxyphenyl)acetyl]-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-23-6 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-4-(3-methoxybenzoyl)-6-[(4-oxo-2-thioxo-5-

thiazolidinylidene) methyl] - (9CI) (CA INDEX NAME)

RN 719309-24-7 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(3,4,5-trimethoxybenzoyl)- (9CI) (CA INDEX NAME)

RN 719309-25-8 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-4-(3-methylbenzoyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-26-9 CAPLUS

CN 2H-1,4-Benzoxazine, 4-([1,1'-biphenyl]-4-ylcarbonyl)-3,4-dihydro-6-[(4-oxo-

2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-27-0 CAPLUS

CN 2H-1,4-Benzoxazine, 4-[4-(1,1-dimethylethyl)benzoyl]-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-28-1 CAPLUS

CN 2H-1,4-Benzoxazine, 4-(4-ethylbenzoyl)-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-29-2 CAPLUS

CN 2H-1,4-Benzoxazine, 4-(4-hexylbenzoyl)-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-30-5 CAPLUS

CN 2H-1,4-Benzoxazine, 4-(4-cyanobenzoyl)-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-31-6 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-4-(2-naphthalenylcarbonyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-32-7 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-4-(1-oxo-2-phenylbutyl)-6-[(4-oxo-2-thioxo-

5-thiazolidinylidene)methyl] - (9CI) (CA INDEX NAME)

RN 719309-33-8 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-4-(2-methyl-1-oxopropyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-34-9 CAPLUS

CN 2H-1,4-Benzoxazine, 4-(cyclopropylcarbonyl)-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-35-0 CAPLUS

CN 2H-1,4-Benzoxazine, 4-(cyclopentylcarbonyl)-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-36-1 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-4-(1-oxoheptyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-37-2 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(2-thienylacetyl)- (9CI) (CA INDEX NAME)

RN 719309-38-3 CAPLUS

CN 2H-1,4-Benzoxazine, 4-(3-cyclopentyl-1-oxopropyl)-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-39-4 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-4-(1-oxo-3-phenyl-2-propenyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-40-7 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(phenoxyacetyl)- (9CI) (CA INDEX NAME)

RN 719309-41-8 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-[(phenylmethoxy)acetyl]- (9CI) (CA INDEX NAME)

RN 719309-42-9 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-[(phenylthio)acetyl]- (9CI) (CA INDEX NAME)

RN 719309-43-0 CAPLUS

CN 2H-1,4-Benzoxazine, 4-(2-furanylcarbonyl)-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-44-1 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(2-thienylcarbonyl)- (9CI) (CA INDEX NAME)

RN 719309-45-2 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(2-quinoxalinylcarbonyl)- (9CI) (CA INDEX NAME)

RN 719309-46-3 CAPLUS

CN 4H-1,4-Benzoxazine-4-octanoic acid, 2,3-dihydro-η-oxo-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 719309-47-4 CAPLUS

CN 2H-1,4-Benzoxazine, 4-[3,5-bis(trifluoromethyl)benzoyl]-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-48-5 CAPLUS

CN 2H-1,4-Benzoxazine, 4-(3,5-difluorobenzoyl)-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-49-6 CAPLUS

CN 2H-1,4-Benzoxazine, 4-[(4-chlorophenoxy)acetyl]-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-50-9 CAPLUS

CN 2H-1,4-Benzoxazine, 4-[(2,2-difluoro-1,3-benzodioxol-5-yl)carbonyl]-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-51-0 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-4-(5-isoxazolylcarbonyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-52-1 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxylic acid, 2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-, 4-(methoxycarbonyl)phenyl ester (9CI) (CA INDEX NAME)

RN 719309-53-2 CAPLUS CN 2H-1,4-Benzoxazine, 4-[(2,5-dichloro-3-thienyl)carbonyl]-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-54-3 CAPLUS
CN 2H-1,4-Benzoxazine, 3,4-dihydro-4-[(5-methyl-3-isoxazolyl)carbonyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-55-4 CAPLUS

CN 2H-1,4-Benzoxazine, 4-[(3-chloro-2-thienyl)carbonyl]-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-56-5 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(2-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

RN 719309-57-6 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, 2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 719309-58-7 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, 2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-N-[2-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

RN 719309-59-8 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, 2,3-dihydro-N-(4-methylphenyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-60-1 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, 2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-N-phenyl- (9CI) (CA INDEX NAME)

RN 719309-61-2 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, 2,3-dihydro-N-(3-methoxyphenyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-62-3 CAPLUS

CN 2H-1,4-Benzoxazine, 4-[[(7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methyl]sulfonyl]-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-63-4 CAPLUS

CN 2H-1,4-Benzoxazine, 4-(2,1,3-benzoxadiazol-5-ylcarbonyl)-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-64-5 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, 2,3-dihydro-N-octyl-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

S
$$\sim$$
 CH \sim O \sim CH \sim O \sim O

RN 719309-65-6 CAPLUS

CN 2H-1,4-Benzoxazine, 4-(3,5-dichlorobenzoyl)-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-66-7 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, 2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-N-[2-(2-thienyl)ethyl]- (9CI) (CA INDEX NAME)

RN 719309-67-8 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, 2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)

RN 719309-68-9 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, 2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

RN 719309-69-0 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, N-(3,5-dimethoxyphenyl)-2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-70-3 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, N-cyclopentyl-2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-71-4 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxylic acid, 2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-, 1-naphthalenyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & &$$

RN 719309-72-5 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-4-(1-oxo-3-phenylpropyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-73-6 CAPLUS

CN 2H-1,4-Benzoxazine, 4-(1,3-benzodioxol-5-ylcarbonyl)-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-74-7 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-4-[4-(methylsulfonyl)benzoyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

5

RN 719309-75-8 CAPLUS

CN 2H-1,4-Benzoxazine, 4-[(3,5-dimethoxyphenyl)acetyl]-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-76-9 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-4-[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-77-0 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, N-(3,4-dimethoxyphenyl)-2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-78-1 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, N-(3,5-dichlorophenyl)-2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-79-2 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, N-(4-chlorophenyl)-2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-80-5 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, N-(3,4-dichlorophenyl)-2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-81-6 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, N-(3,5-dimethylphenyl)-2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-82-7 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, N-(3-chlorophenyl)-2,3-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-83-8 CAPLUS

CN 2H-1,4-Benzoxazine, 4-[3,5-bis(1,1-dimethylethyl)benzoyl]-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-84-9 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-4-(1-oxo-4-phenylbutyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-85-0 CAPLUS

CN 2H-1,4-Benzoxazine, 4-(cycloheptylcarbonyl)-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-86-1 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-4-(1-oxo-2-phenylpropyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-87-2 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-4-[(3-methylcyclohexyl)carbonyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-88-3 CAPLUS

CN 2H-1,4-Benzoxazine, 4-(2,3-dimethyl-1-oxobutyl)-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-89-4 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-4-[3-(2-methylcyclohexyl)-1-oxopropyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-90-7 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-4-(2-methoxy-5-methylbenzoyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-91-8 CAPLUS

CN 2H-1,4-Benzoxazine, 4-(2-fluoro-5-methylbenzoyl)-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-92-9 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-4-(2,3,3-trimethyl-1-oxobutyl)- (9CI) (CA INDEX NAME)

RN 719309-93-0 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-4-[(2-methylcyclohexyl)carbonyl]-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-94-1 CAPLUS

CN 2H-1,4-Benzoxazine, 4-acetyl-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-95-2 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-4-(1-oxopropyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-96-3 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-4-(1-oxobutyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-97-4 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-4-(1-oxohexyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-98-5 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-4-(1-oxopentyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719309-99-6 CAPLUS

CN 2H-1,4-Benzoxazine, 4-(2,2-dimethyl-1-oxopropyl)-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719310-00-6 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-4-(1-oxononyl)-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
 & & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\
 & & & \\$$

RN 719310-01-7 CAPLUS

CN 2H-1,4-Benzoxazine, 4-(2-ethyl-1-oxohexyl)-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719310-02-8 CAPLUS

CN 2H-1,4-Benzoxazine, 4-[2-(acetyloxy)-1-oxopropyl]-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719310-03-9 CAPLUS

CN 4H-1,4-Benzoxazine-4-butanoic acid, 2,3-dihydro-γ-oxo-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 719310-04-0 CAPLUS

CN 2H-1,4-Benzoxazine, 4-[(1-acetyl-4-piperidinyl)carbonyl]-3,4-dihydro-6-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719310-05-1 CAPLUS

CN 4-Thiazolidinone, 5-[(2,3,4,5-tetrahydro-1,5-benzoxazepin-8-yl)methylene]-2-thioxo- (9CI) (CA INDEX NAME)

RN 719310-06-2 CAPLUS

CN 1,5-Benzoxazepine, 5-(cyclopropylcarbonyl)-2,3,4,5-tetrahydro-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719310-07-3 CAPLUS

CN 1,5-Benzoxazepine-5(2H)-carboxylic acid, 3,4-dihydro-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-, phenyl ester (9CI) (CA INDEX NAME)

RN 719310-08-4 CAPLUS

CN 1,5-Benzoxazepine-5(2H)-carboxylic acid, 3,4-dihydro-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-, 1-naphthalenyl ester (9CI) (CA INDEX NAME)

RN 719310-09-5 CAPLUS

CN 1,5-Benzoxazepine-5(2H)-carboxylic acid, 3,4-dihydro-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-, 4-methylphenyl ester (9CI) (CA INDEX NAME)

RN 719310-10-8 CAPLUS

CN 1,5-Benzoxazepine-5(2H)-carboxylic acid, 3,4-dihydro-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-, 4-(methoxycarbonyl)phenyl ester (9CI) (CA INDEX NAME)

RN 719310-11-9 CAPLUS
CN 1,5-Benzoxazepine, 5-[(4-chlorophenoxy)acetyl]-2,3,4,5-tetrahydro-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719310-12-0 CAPLUS
CN 1,5-Benzoxazepine-5(2H)-carboxamide, 3,4-dihydro-N-(4-methylphenyl)-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719310-13-1 CAPLUS

CN 1,5-Benzoxazepine, 5-(cyclopentylcarbonyl)-2,3,4,5-tetrahydro-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719310-14-2 CAPLUS

CN 1,5-Benzoxazepine, 2,3,4,5-tetrahydro-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-5-(2-thienylacetyl)- (9CI) (CA INDEX NAME)

RN 719310-15-3 CAPLUS

CN 1,5-Benzoxazepine-5(2H)-carboxamide, N-(3,5-dimethoxyphenyl)-3,4-dihydro-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719310-16-4 CAPLUS

CN 1,5-Benzoxazepine, 5-(3,4-dichlorobenzoyl)-2,3,4,5-tetrahydro-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719310-17-5 CAPLUS

CN 1,5-Benzoxazepine, 2,3,4,5-tetrahydro-5-(1-oxo-3-phenyl-2-propenyl)-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719310-18-6 CAPLUS

CN 1,5-Benzoxazepine, 5-(2,1,3-benzoxadiazol-5-ylcarbonyl)-2,3,4,5-tetrahydro-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719310-19-7 CAPLUS

CN 1,5-Benzoxazepine, 2,3,4,5-tetrahydro-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-5-(3-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

RN 719310-20-0 CAPLUS

CN 1,5-Benzoxazepine-5(2H)-carboxamide, 3,4-dihydro-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

RN 719310-21-1 CAPLUS

CN 1,5-Benzoxazepine, 2,3,4,5-tetrahydro-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-5-[(phenylmethoxy)acetyl]- (9CI) (CA INDEX NAME)

RN719310-22-2 CAPLUS

CN1,5-Benzoxazepine-5(2H)-carboxamide, N-[4-chloro-2-(trifluoromethyl)phenyl]-3,4-dihydro-7-[(4-oxo-2-thioxo-5thiazolidinylidene)methyl] - (9CI) (CA INDEX NAME)

719310-23-3 CAPLUS RN

1,5-Benzoxazepine, 5-(4-cyanobenzoyl)-2,3,4,5-tetrahydro-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME) CN

RN719310-24-4 CAPLUS

CN 1,5-Benzoxazepine-5(2H)-carboxamide, 3,4-dihydro-N-(3-methoxyphenyl)-7-[(4oxo-2-thioxo-5-thiazolidinylidene)methyl] - (9CI) (CA INDEX NAME)

RN 719310-25-5 CAPLUS

CN 1,5-Benzoxazepine, 5-(2-furanylcarbonyl)-2,3,4,5-tetrahydro-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719310-26-6 CAPLUS

CN 1,5-Benzoxazepine, 2,3,4,5-tetrahydro-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-5-[1-oxo-3-[3-(trifluoromethyl)phenyl]-2-propenyl]- (9CI) (CA INDEX NAME)

RN 719310-27-7 CAPLUS

CN 1,5-Benzoxazepine, 5-[[5-(1,1-dimethylethyl)-2-methyl-3-furanyl]carbonyl]-2,3,4,5-tetrahydro-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719310-28-8 CAPLUS

CN 1,5-Benzoxazepine, 5-(4-hexylbenzoyl)-2,3,4,5-tetrahydro-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

RN 719310-29-9 CAPLUS

CN 1,5-Benzoxazepine, 5-[(9,10-dihydro-9,10-dioxo-2-anthracenyl)carbonyl]-2,3,4,5-tetrahydro-7-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]- (9CI) (CA INDEX NAME)

REFERENCE COUNT:

5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:291950 CAPLUS

DOCUMENT NUMBER: 140:31504

TITLE: Pin1-modulating compounds and methods of use for the

treatment of Pin1-associated diseases, including

cancer

INVENTOR(S): Mckee, Timothy D.; Suto, Robert K.; Tibbitts, Thomas;

Sowadski, Janusz

PATENT ASSIGNEE(S): Pintex Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 166 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent English

LANGUAGE:

Englis

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

]	PATEI	NT I	. O <i>l</i>			KIND DATE														
	WO 2004028535					A1 20040408						 US66								
	1	₩:	ΑE,	AG,	AL,	AM,	ΑT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,		
			CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,		
			GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KP,	KR,	ΚZ,	LC,	LK,	LR,		
			LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	ΜZ,	NO,	NZ,	OM,	PH,		
			PL,	PΤ,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	ТJ,	TM,	TN,	TR,	TT,	TZ,		
			UA,	UG,	UZ,	VC,	VN,	ΥU,	ZA,	ZM,	ZW									
	1	RW:	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	ŪĠ,	ZM,	ZW,	AM,	ΑZ,	BY,		
			KG,	ΚZ,	MD,	RU,	TJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,		
			FI,	FR,	GB,	GR,	HU,	ΙE,	IT,	LU,	MC,	NL,	PT,	RO,	SE,	SI,	SK,	TR,		
			BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG		
US 2004214872						A1		2004	1028	1	US 2	003-3	3794	20030303						
F	EP 1551396						A1 20050713]	EP 2	003-	7986	53		20030303				
	I	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,		
			ΙE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR,	BG,	CZ,	EE,	HU,	SK			
PRIORITY APPLN. INFO.:										1	US 2002-414077P					P 2	0020	926		
										WO 2003-US6675						W 2	0030	303		

OTHER SOURCE(S): MARPAT 140:315042

AB The invention is directed to modulators, e.g., inhibitors, of Pin1 and Pin1-related proteins and the use of such modulators for treatment of Pin1 associated states, e.g., for the treatment of cancer. Synthetic methods are included.

IT 676646-30-3 677004-75-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Pin1-modulating compds. for treatment of Pin1-associated diseases, including cancer)

RN 676646-30-3 CAPLUS

CN 3-Thiazolidinebutanoic acid, 4-oxo-5-(6-quinoxalinylmethylene)-2-thioxo-(9CI) (CA INDEX NAME)

SSCHCH
$$\sim$$
 N \sim N \sim

RN 677004-75-0 CAPLUS

CN 3-Thiazolidinebutanoic acid, 5-[(3,4-dihydro-4-methyl-2H-1,4-benzoxazin-7-

yl)methylene]-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)

2

SSCHCHO2C- (CH₂) 3
$$CH$$

REFERENCE COUNT:

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:60505 CAPLUS

DOCUMENT NUMBER: 140:128412

TITLE: Preparation of azolidinone-vinyl fused-benzene

derivatives for therapeutic uses as PI3 kinase

inhibitors

INVENTOR(S): Rueckle, Thomas; Jiang, Xuliang; Gaillard, Pascale;

Church, Dennis; Vallotton, Tania

PATENT ASSIGNEE(S): Applied Research Systems Ars Holding N.V., Neth.

Antilles

SOURCE: PCT Int. Appl., 142 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

LANGUAGE:

Patent English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

	PATENT NO.)	DATE			APPL	ICAT	ION 1	DATE					
	WO	2004	A1 20040122			1	WO 2	2003-1	EP50:	20030710									
		W:	ΑE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,	
			CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	
			GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KΕ,	KG,	ΚP,	KR,	KZ,	LC,	LK,	LR,	
			LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NI,	NO,	NZ,	OM,	
			PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,	
			TZ,	UA,	ŪĠ,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW						
		RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	ΑZ,	BY,	
			KG,	ΚZ,	MD,	RU,	ТJ,	TM,	AT,	ΒE,	ВG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	
			FI,	FR,	GB,	GR,	HU,	ΙE,	IT,	LU,	MC,	NL,	PT,	RO,	SE,	SI,	SK,	TR,	
			BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG	
	US	2004	0925	51		A1 20040513				•	US 2	2002-2	2899	20021107					
	CA	2493	843			AA 20040122					CA 2	2003-2	2493	20030710					
	BR	2003	0127	52		Α		2005	0426		BR 2	2003-	1275	20030710					
	BR 2003012650					Α		2005	0503	:	BR 2	2003-	1265	20030710					
	ΕP	EP 1549644				A1 20050706					EP 2	2003-	7639	20030710					
		R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
			ΙE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR,	BG,	CZ,	EE,	HU,	SK		
	JP	2005	5381	88		T2		2005	1215		JP 2	2005-	5050	76	20030710				
	NO 2005000654						A 20050315				NO 2	2005-0	654		20050208				
PRIOR	RIORITY APPLN. INFO.:										EP 2	2002-	1007	98		A 2	0020	710	
										•	US 2	2002-2	2899	98		A 2	0021	107	
							1	WO 2	2003-1	EP50	302	1	W 2	0030	710				
OTHER	OTHER SOURCE(S):						ТАЧ	140:	1284	12									

OTHER SOURCE(S):

MARPAT 140:128412

GI

AB The present invention is related to the preparation of azolidinedione-vinyl fused-benzene derivs., such as I [R1 = H, CN, carboxy, acyl, alkoxy, halogen, acyloxy, etc.; A = fused heterocyclic or carbocyclic ring; Y1, Y2

= S, O, NH], and their use in pharmaceutical compns. as PI3 kinase (PI3K) inhibitors. These azolidinones are claimed for use in the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, cancer, graft rejection, lung injuries, chronic obstructive pulmonary disease, anaphylactic shock, fibrosis, psoriasis, allergic diseases, asthma, stroke or ischemic conditions, ischemia-reperfusion, platelet aggregation/activation, skeletal muscle atrophy/hypertrophy, leukocyte recruitment in cancer tissue, angiogenesis, invasion metastasis in melanoma and Kaposi's sarcoma, sepsis, transplantation, pancreatitis, multi-organ failure, glomerulosclerosis, glomerulonephritis, progressive renal fibrosis, endothelial and epithelial injuries in the lung or in general lung airways inflammation. Further, these azolidinones are claimed for use in the treatment of atherosclerosis, hypertrophy, cardiac myocyte dysfunction, elevated blood pressure, vasoconstriction, Alzheimer's disease, Huntington's disease, CNS trauma, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, thrombosis, and brain infection/inflammation such as meningitis or encephalitis. Thus, azolidinone II was prepared via a condensation reaction of piperonal with 2,4-thiazolidinedione using β -alanine in acetic acid and stirring at 100° for 3 h. Some of the prepared azolidinones were assayed for PI3Ky inhibition using a high throughput PI3K lipid kinase binding assay. Tablet, capsule, liquid and injectable pharmaceutical compns. were presented.

IT 648915-83-7P

CN

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of azolidinone-vinyl fused-benzene derivs. for use in pharmaceutical compns. as PI3 kinase inhibitors)

RN 648915-83-7 CAPLUS

2,4-Thiazolidinedione, 5-[(3,4-dihydro-2H-1,4-benzoxazin-6-yl)methylene]-(9CI) (CA INDEX NAME)

IT 648450-29-7P 648450-30-0P 648450-59-3P 648450-60-6P 648915-84-8P 648915-85-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of azolidinone-vinyl fused-benzene derivs. for use in pharmaceutical compns. as PI3 kinase inhibitors)

RN 648450-29-7 CAPLUS

CN 2,4-Thiazolidinedione, 5-(6-quinoxalinylmethylene)- (9CI) (CA INDEX NAME)

RN 648450-30-0 CAPLUS

CN 4-Thiazolidinone, 5-(6-quinoxalinylmethylene)-2-thioxo- (9CI) (CA INDEX NAME)

RN 648450-59-3 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxylic acid, 6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-2,3-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 648450-60-6 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxylic acid, 6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 648915-84-8 CAPLUS

CN 2H-1,4-Benzoxazine, 4-benzoyl-6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-3,4-dihydro-(9CI) (CA INDEX NAME)

RN 648915-85-9 CAPLUS
CN 2H-1,4-Benzoxazine, 4-acetyl-6-[(2,4-dioxo-5-thiazolidinylidene)methyl]-3,4-dihydro-(9CI) (CA INDEX NAME)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:60305 CAPLUS

DOCUMENT NUMBER: 140:128411

Preparation of dioxothiazolylidenemethyl derivatives TITLE:

for increasing spermatozoa motility

INVENTOR(S): De Luca, Giampiero

PATENT ASSIGNEE(S): Applied Research Systems Ars Holding NV, Neth.

Antilles

SOURCE: PCT Int. Appl., 131 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

LANGUAGE:

Patent English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA	TENT :	KIND DATE																	
WO				A1 2004			0122	.22 WO 2003-EP50303											
	W:	ΑE,	AG,	AL,	AM,	AT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,		
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,		
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	ΚP,	KR,	KZ,	LC,	LK,	LR,		
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	ΜZ,	NI,	NO,	ΝZ,	OM,		
		PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,	TJ,	TM,	TN,		
		TR,	TT,	ΤZ,	UA,	UG,	US,	UΖ,	VC,	VN,	YU,	ZA,	ZM,	ZW					
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	ŪĠ,	ZM,	ZW,	AM,	ΑZ,	BY,		
		KG,	ΚZ,	MD,	RU,	TJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DΕ,	DK,	EE,	ES,		
		FI,	FR,	GB,	GR,	HU,	ΙE,	IT,	LU,	MC,	NL,	PT,	RO,	SE,	SI,	SK,	TR,		
		BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG		
CA	CA 2489779					AA 20040122				CA 2	2003-2	2489	20030710						
EP	EP 1531813					A1 20050525				EP 2	2003-	7639	20030710						
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,		
		ΙE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR,	BG,	CZ,	EE,	HU,	SK			
JP	JP 2006500327						2006	0105		JP 2	2004-	5206	20030710						
NO	NO 2005000713						2005	0210]	NO 2	2005-'	713	20050210						
US	US 2005222225						A1 20051006				2005-	5196	20050504						
PRIORIT	PRIORITY APPLN. INFO.:									EP 2	2002-3	1007	99	7	A 2	0020	710		
					:	EP 2	2002-3	1028	76	7	A 2	0021	223						
									1	WO 2	2003-1	EP50	303	1	₩ 2	0030	710		
OTHER S		MARPAT 140:128411																	

GI

AB Title compds. I [X = S, O, NH; Y1-2 = S, O, NH; Cy = 5-8 membered,optionally fused, carbo/heterocyclic ring] are prepared For instance, thiazolidine-2,4-dione is condensed with piperonal (HOAc, β -alanine, 3 h, 100°) to give II. Selected examples have IC50 < 1 μM for the phosphatidylinositol-3-kinase (PI3Kγ) receptor. I are useful

for the improvement of spermatozoa fertilization activity; in particular for the increase of spermatozoa motility. Furthermore, I are used to treat infertility and assisted reproduction techniques (ART). IT 648450-29-7P, 5-(Quinoxalin-6-ylmethylene)thiazolidine-2,4-dione 648450-30-0P, 5-(Quinoxalin-6-ylmethylene)-2-thioxothiazolidin-4one 648450-59-3P, 6-(2,4-Dioxothiazolidin-5-ylidenemethyl)-2,3dihydrobenzo[1,4]oxazine-4-carboxylic acid tert-butyl ester 648450-60-6P, 6-(2,4-Dioxothiazolidin-5ylidenemethyl)benzo[1,4]oxazine-4-carboxylic acid tert-butyl ester RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of dioxothiazolylidenemethyl derivs. for increasing spermatozoa motility)

648450-29-7 CAPLUS RN

CN 2,4-Thiazolidinedione, 5-(6-quinoxalinylmethylene)- (9CI) (CA INDEX NAME)

RN 648450-30-0 CAPLUS

4-Thiazolidinone, 5-(6-quinoxalinylmethylene)-2-thioxo- (9CI) (CA INDEX CN NAME)

648450-59-3 CAPLUS RN

4H-1,4-Benzoxazine-4-carboxylic acid, 6-[(2,4-dioxo-5-CN thiazolidinylidene) methyl] -2,3-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 648450-60-6 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxylic acid, 6-[(2,4-dioxo-5thiazolidinylidene) methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

5

REFERENCE COUNT:

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT